<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137763">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01769781</url>
  </required_header>
  <id_info>
    <org_study_id>CR013-01</org_study_id>
    <nct_id>NCT01769781</nct_id>
  </id_info>
  <brief_title>Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence</brief_title>
  <official_title>Treatment of Patients With Endometriosis Recurrence With Aromatase Inhibitor (Anastrazole) Plus GnRH-agonist (Luprolide).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Endocrinology and Reproductive Medicine, Italy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Endocrinology and Reproductive Medicine, Italy</source>
  <oversight_info>
    <authority>Italy: National Monitoring Centre for Clinical Trials - Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will
      be tested for the treatment of women with endometriosis recurrence compared with classical
      GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up
      will be the outcomes for establishing which medical treatment is the best in endometriosis
      recurrence treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endometriosis is a chronic disease affecting 5-10% of women in reproductive age, showing
      recurrence after surgery at least in 20-50% after 5 years of follow-up. Aromatase inhibitor
      plus GnRH analog may be more effective than GnRH agonist alone in the treatment of
      endometriosis recurrence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>disease free time</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>time without pain symptoms due to the disease recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time of pain disappearance</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>time needed during treatment to improve pain symptoms</description>
  </secondary_outcome>
  <other_outcome>
    <measure>reduction of endometriosis lesions</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>endometriosis lesions regression during treatment evidenced by MRI scan</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Endometriosis</condition>
  <arm_group>
    <arm_group_label>anastrazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>women with endometriosis recurrence will be treated with Leuprolide acetate 11,25mg plus anastrazole 1mg/day for three months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRH analog alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>women with endometriosis recurrence will be treated with leuprolide acetate 11.25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrazole</intervention_name>
    <description>combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months</description>
    <arm_group_label>anastrazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH analog alone</intervention_name>
    <description>treatment for three months with GnRH analog (leuprolide acetate) alone</description>
    <arm_group_label>GnRH analog alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women affected by endometriosis showing recurrence of pain symptoms, previous surgery
             for endometriosis

        Exclusion Criteria:

          -  presence of other systemic diseases
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>marco sbracia, md</last_name>
    <role>Study Chair</role>
    <affiliation>CERM-HUNGARIA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cerm-Hungaria</name>
      <address>
        <city>Rome</city>
        <zip>00153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FABIO SCARPELLINI, MD</last_name>
      <phone>+39-3278779064</phone>
      <email>quelidebercia@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>MARCO SBRACIA, MD</last_name>
      <phone>+39-3479037433</phone>
      <email>marcandrea@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>FABIO SCARPELLINI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 4, 2013</lastchanged_date>
  <firstreceived_date>January 15, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Endocrinology and Reproductive Medicine, Italy</investigator_affiliation>
    <investigator_full_name>Fabio Scarpellini</investigator_full_name>
    <investigator_title>PRINCIPAL INVESTIGATOR</investigator_title>
  </responsible_party>
  <keyword>endometriosis recurrence</keyword>
  <keyword>pelvic pain</keyword>
  <keyword>aromatase inhibitor</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Deslorelin</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
